A margin of approximately 26% at constant currency, with increased confidence to navigate a volatile environment.









“Galderma’s strong first quarter results reflect our commitment to advancing dermatology and delivering innovative solutions for consumers and patients worldwide. This marks a strong start to another year of key launches, sustained execution and scientific momentum, as well as the continued strengthening of our financial profile – all reinforcing our category leadership. Our integrated dermatology strategy continues to drive growth and we are well-positioned to build on this success throughout 2026.”



FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA









Commercial performance

Galderma expects 2026 to be another year of
=*=*=*=*=*=
当前为第3/27页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页